Please enable Javascript
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Follicular Lymphoma
The latest news, research, and perspectives in follicular lymphoma (FL).
Advertisement
Incidental Follicular Lymphoma Diagnosis Associated With Earlier-Stage Disease
Melissa Badamo
Follicular Lymphoma
|
July 8, 2025
The study investigated the role of multi-cancer early detection tests (MCEDs) on patient survival outcomes.
Read More
Bridging the Gap: NCCN Summit Advocates for Primary Care and Oncology Collaboration to Improve Patient Outcomes
Melissa Badamo
Acute Lymphoblastic Leukemia
|
July 7, 2025
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Read More
FDA Approval of Tafa R2 Makes History in R/R Follicular Lymphoma
Nichole Tucker
Follicular Lymphoma
|
June 27, 2025
FDA approves tafasitamab plus R2 for relapsed FL, showing 57% reduced risk of progression in phase 3 inMIND trial.
Read More
FDA OKs Tafasitamab Combo for Relapsed Follicular Lymphoma
Melissa Badamo
Follicular Lymphoma
|
June 25, 2025
The approval of tafasitamab-cxix in combination with rituximab and lenalidomide was based on the phase 3 inMIND trial.
Read More
Subcutaneous Mosunetuzumab Shows Strong Efficacy in First-Line High-Tumor Burden Follicular Lymphoma Care
Izzah Nawaz
Follicular Lymphoma
|
June 13, 2025
Mosunetuzumab’s mechanism of action involves connecting B-cells with T-cells for elimination by the immune system.
Read More
Do Blood Immune Biomarkers Predict Response to Mosunetuzumab for FL, MZL?
Andrew Moreno
Meeting News
|
June 5, 2025
Peripheral blood samples were analyzed within a phase 2 trial of this bispecific antibody as 1L treatment for FL and MZL.
Read More
Advertisement
Odronextamab Shows Durable Response in Relapsed Follicular Lymphoma
Melissa Badamo
Follicular Lymphoma
|
June 3, 2025
Of 128 efficacy-evaluable patients, the ORR was 80.5% and the CR rate was 74.2% at a median follow-up of 28.3 months.
Read More
Trial Work Progressing and Encouraging for Zilovertamab Vedotin Combo in DLBCL
Andrew Moreno
Meeting News
|
June 1, 2025
A phase 2/3 trial is evaluating zilovertamab vedotin plus rituximab and gemcitabine-oxaliplatin in relapsed/refractory DLBCL.
Read More
Continuous Medicaid Coverage Associated With Lower Incidence of Stage IV Lymphoma Among Children and Young Adults
Melissa Badamo
Aggressive B-Cell Lymphoma
|
May 27, 2025
Steady access to Medicaid insurance helps ensure early recognition of symptoms, said senior author Xu Ji, PhD.
Read More
FDA ODAC: STARGLO Glofitamab DLBCL Trial Inapplicable for US Populations
Andrew Moreno
Aggressive B-Cell Lymphoma
|
May 23, 2025
The global phase 3 RCT is part of an sBLA for glofitamab plus gemcitabine and oxaliplatin use in R/R DLBCL NOS.
Read More
ZUMA-12 Suggests Axi-Cel May Be Curative in First-Line, High-Risk LBCL
Nichole Tucker
Transplantation & Cellular Therapy
|
May 29, 2025
Axi-cel shows durable response in high-risk LBCL frontline treatment with 80% progression-free at 3 years in ZUMA-12 trial.
Read More
Oncologists Are Resigning at Unprecedented Rates: Are Academic Medical Centers Ready to Respond?
Melissa Badamo
Acute Lymphoblastic Leukemia
|
May 16, 2025
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Read More
LucyRx Expands Specialty Pharmacy Network to Remove Barriers in Cancer Care
Melissa Badamo
Acute Lymphoblastic Leukemia
|
May 8, 2025
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Read More
CD47, CD20-Targeting Bispecific Fusion Protein Evaluated for Refractory NHL in First-in-Human Trial
Andrew Moreno
Aggressive B-Cell Lymphoma
|
April 30, 2025
Efficacy and safety profile data were presented at the AACR Annual Meeting 2025.
Read More
ASCO Seeks Cooperation with Federal Health Agencies’ New Leaders To Improve US Cancer Care
Andrew Moreno
Transplantation & Cellular Therapy
|
April 25, 2025
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Read More
Unpacking the COA Prescription for Health Care Reform: What Does it Mean for Patients and Oncologists?
Melissa Badamo
Acute Lymphoblastic Leukemia
|
April 23, 2025
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
Read More
NCCN Foundation Announces 2025 Young Investigator Award Recipients
Melissa Badamo
Print
|
April 14, 2025
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Read More
What Is the Outlook for T-Cell–Engaging Interventions for Lymphoma Management?
Nirav Shah, MD, MSHP
Transplantation & Cellular Therapy
|
April 15, 2025
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
View More
What Is the Role of Palliative Care for Patients With Hematologic Malignancies?
Melissa Badamo
Video Insights
|
April 15, 2025
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
View More
Oncologists Convene at Capitol Hill to Advocate for Cancer Care Policies
Melissa Badamo
Acute Lymphoblastic Leukemia
|
April 8, 2025
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Read More
Load More
Advertisement
Advertisement